NCT05242081

Brief Summary

The purpose of this study was to observe the effects of opioid-free anesthesia with S-ketamine on postoperative analgesia and perioperative hemodynamics in short surgical operations, and to explore the effects of S-ketamine on postoperative awakening time and extubation time, nausea and vomiting, hypoxemia, and delirium.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
980

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 13, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 16, 2022

Completed
5 months until next milestone

Study Start

First participant enrolled

July 1, 2022

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2022

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2023

Completed
Last Updated

July 20, 2022

Status Verified

July 1, 2022

Enrollment Period

5 months

First QC Date

January 13, 2022

Last Update Submit

July 19, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • The probability of numerical rating scale (NRS) score being less than or equal to 3 when leaving the Postanesthesia Care Unit (PACU)

    The probability of numerical rating scale (NRS) score being less than or equal to 3 when leaving the Postanesthesia Care Unit (PACU)

    1 day of the surgery

Secondary Outcomes (13)

  • The area under the curve (AUC) of mean arterial pressure (MAP) within 10 minutes after induction is lower than the baseline mean arterial pressure (MAP 3 minutes before induction).

    From the date of the beginning of anesthesia until the date of the end of anesthesia, assessed up to 2 days

  • herat rate and blood pressure during the surgery every 5 minutes

    From the date of the beginning of anesthesia until the date of the end of anesthesia, assessed up to 2 days

  • Total dosage of anesthesia drug

    From the date of the beginning of anesthesia until the date of the end of anesthesia, assessed up to 2 days

  • Total dosage of vasoactive agents

    From the date of the beginning of anesthesia until the date of the end of anesthesia, assessed up to 2 days

  • The duration of surgery

    From the date of the beginning of surgery until the date of the end of surgery, assessed up to 2 days

  • +8 more secondary outcomes

Study Arms (2)

S-ketamine

EXPERIMENTAL
Drug: S-ketamine

Sufentanil

ACTIVE COMPARATOR
Drug: Sufentanil

Interventions

S-ketamine 0.5mg/kg for induction and 0.2mg/kg/h for maintenance

S-ketamine

Sufentanil 0.2-0.3μg/kg for induction and remifentanil 0.05-0.15μg/kg/min for maintenance

Sufentanil

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged from 18 years to 65 years
  • American society of anesthesiologists physical status classification I-II
  • Patients scheduled for elective laparoscopic cholecystectomy
  • Willing to sign informed consent

You may not qualify if:

  • Allergic to narcotic drugs;
  • Surgical history within the past 1 month;
  • patients with neurological diseases or mental disorders;
  • Unable to understand numerical rating Scale (NRS);
  • patients with untreated or poorly controlled hypertension (arterial hypertension, resting systolic/diastolic blood pressure over 180/100mmHg);
  • patients with untreated or undertreated hyperthyroidism;
  • Patients with unstable angina pectoris or myocardial infarction in the past 6 months;
  • When intraocular pressure is high (glaucoma) and penetrating ocular trauma, intraocular pressure cannot rise.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, 210029, China

RECRUITING

MeSH Terms

Interventions

EsketamineSufentanil

Intervention Hierarchy (Ancestors)

FentanylPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 13, 2022

First Posted

February 16, 2022

Study Start

July 1, 2022

Primary Completion

December 1, 2022

Study Completion

June 1, 2023

Last Updated

July 20, 2022

Record last verified: 2022-07

Locations